pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

3,311 catalysts · 4,728 grant · 3,350 8k filing · 2,834 device 510k · 2,727 approval · 2,000 device recall · 1,989 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 0 catalysts2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: earnings×type: approval×from 2025-05-29×clear all
type
  • grant4,728
  • 8k filing3,350
  • device 510k2,834
  • approval2,727
  • device recall2,000
  • device pma1,989
device adverse event
1,000
  • recall693
  • earnings584
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of May 26, 2025

    3
    ›May 29, 2025approval444d agoFOCINVEZ (FOSAPREPITANT DIMEGLUMINE) — FDA approvalAthenex Inc (Inactive)

    Sponsor: STERISCIENCE. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›May 29, 2025approval444d agoMETHOTREXATE — FDA approvalMaxtrex

    Sponsor: ACCORD HLTHCARE. Form: SOLUTION. Route: INTRAVENOUS

    full page →Maxtrex →fda approvals ↗
    ›May 30, 2025approval443d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

    Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

    full page →ACETAZOLAMIDE →fda approvals ↗

    Week of Jun 2, 2025

    5
    ›Jun 3, 2025approval439d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Jun 3, 2025approval

    Week of Jun 9, 2025

    13
    ›Jun 9, 2025approval433d agoCOLUMVI (GLOFITAMAB-GXBM) — FDA approvalglofitamab

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →glofitamab →fda approvals ↗
    ›Jun 10, 2025approval

    Week of Jun 16, 2025

    11
    ›Jun 16, 2025approval426d agoARYNTA (LISDEXAMFETAMINE DIMESYLATE) — FDA approvalLISDEXAMFETAMINE DIMESYLATE

    Sponsor: AZURITY. Form: SOLUTION. Route: ORAL

    full page →LISDEXAMFETAMINE DIMESYLATE →fda approvals ↗
    ›Jun 17, 2025approval

    Week of Jun 23, 2025

    14
    ›Jun 23, 2025approval419d agoAMITRIPTYLINE HYDROCHLORIDE — FDA approvalAlgoTherapeutix SAS

    Sponsor: UNIQUE PHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 23, 2025approval

    Week of Jun 30, 2025

    3
    ›Jul 1, 2025approval411d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Jul 1, 2025approval

    Week of Jul 7, 2025

    1
    ›Jul 8, 2025approval404d agoELREXFIO (ELRANATAMAB) — FDA approvalelranatamab

    Sponsor: PFIZER INC. Form: SOLUTION. Route: INJECTION

    full page →elranatamab →fda approvals ↗
    ← prev
    page 1 of 67
    next →
    439d ago
    ISOTRETINOIN — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: ACTAVIS LABS FL. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jun 3, 2025approval439d agoMYORISAN (ISOTRETINOIN) — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: UPSHER SMITH LABS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jun 6, 2025approval436d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Jun 6, 2025approval436d agoOPUVIZ (AFLIBERCEPT-YSZY) — FDA approvalOPUVIZ

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →OPUVIZ →fda approvals ↗
    432d ago
    QULIPTA (ATOGEPANT) — FDA approvalatogepant

    Sponsor: ABBVIE. Form: TABLET. Route: ORAL

    full page →atogepant →fda approvals ↗
    ›Jun 10, 2025approval432d agoQULIPTA (ATOGEPANT) — FDA approvalatogepant

    Sponsor: ABBVIE. Form: TABLET. Route: ORAL

    full page →atogepant →fda approvals ↗
    ›Jun 12, 2025approval430d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Jun 12, 2025approval430d agoVOQUEZNA TRIPLE PAK (AMOXICILLIN) — FDA approvalamoxicillin + clarithromycin + vonoprazan

    Sponsor: PHATHOM. Form: CAPSULE, TABLET, TABLET. Route: ORAL

    full page →amoxicillin + clarithromycin + vonoprazan →fda approvals ↗
    ›Jun 12, 2025approval430d agoVOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approvalamoxicillin + vonoprazan fumarate

    Sponsor: PHATHOM. Form: CAPSULE, TABLET. Route: ORAL

    full page →amoxicillin + vonoprazan fumarate →fda approvals ↗
    ›Jun 12, 2025approval430d agoDELSTRIGO (DORAVIRINE) — FDA approval(doravirine + lamivudine + tenofovir disoproxil fumarate)

    Sponsor: MSD MERCK CO. Form: TABLET. Route: ORAL

    full page →(doravirine + lamivudine + tenofovir disoproxil fumarate) →fda approvals ↗
    ›Jun 13, 2025approval429d agoCLOZAPINE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: IVAX SUB TEVA PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 13, 2025approval429d agoCLOZAPINE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: IVAX SUB TEVA PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 13, 2025approval429d agoLEVOCETIRIZINE DIHYDROCHLORIDE — FDA approvalLEVOCETIRIZINE DIHYDROCHLORIDE

    Sponsor: MICRO LABS LTD INDIA. Form: TABLET. Route: ORAL

    full page →LEVOCETIRIZINE DIHYDROCHLORIDE →fda approvals ↗
    ›Jun 13, 2025approval429d agoLEVOCETIRIZINE DIHYDROCHLORIDE — FDA approvalLEVOCETIRIZINE DIHYDROCHLORIDE

    Sponsor: MICRO LABS LTD INDIA. Form: TABLET. Route: ORAL

    full page →LEVOCETIRIZINE DIHYDROCHLORIDE →fda approvals ↗
    ›Jun 13, 2025approval429d agoLEVOCETIRIZINE DIHYDROCHLORIDE — FDA approvalLEVOCETIRIZINE DIHYDROCHLORIDE

    Sponsor: MICRO LABS LTD INDIA. Form: TABLET. Route: ORAL

    full page →LEVOCETIRIZINE DIHYDROCHLORIDE →fda approvals ↗
    ›Jun 13, 2025approval429d agoSTEQEYMA (USTEKINUMAB-STBA) — FDA approvalSTEQEYMA

    Sponsor: CELLTRION, INC.. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →STEQEYMA →fda approvals ↗
    425d ago
    XARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jun 17, 2025approval425d agoXARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jun 17, 2025approval425d agoMEFENAMIC ACID — FDA approvalMEFENAMIC ACID

    Sponsor: MICRO LABS. Form: CAPSULE. Route: ORAL

    full page →MEFENAMIC ACID →fda approvals ↗
    ›Jun 17, 2025approval425d agoTREMFYA (GUSELKUMAB) — FDA approvalguselkumab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →guselkumab →fda approvals ↗
    ›Jun 18, 2025approval424d agoDUPIXENT (DUPILUMAB) — FDA approvaldupilumab

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

    full page →dupilumab →fda approvals ↗
    ›Jun 18, 2025approval424d agoZEJULA (NIRAPARIB TOSYLATE) — FDA approvalniraparib

    Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL

    full page →niraparib →fda approvals ↗
    ›Jun 18, 2025approval424d agoZEJULA (NIRAPARIB TOSYLATE) — FDA approvalniraparib

    Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL

    full page →niraparib →fda approvals ↗
    ›Jun 18, 2025approval424d agoISOTRETINOIN — FDA approvalSun Pharmaceutical Industries Ltd

    Sponsor: ACTAVIS LABS FL. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jun 18, 2025approval424d agoENBREL (ETANERCEPT) — FDA approvalAMGEN INC

    Sponsor: IMMUNEX. Form: SYRINGE

    full page →fda approvals ↗
    ›Jun 18, 2025approval424d agoAXTLE (PEMETREXED DIPOTASSIUM) — FDA approvalAXTLE

    Sponsor: AVYXA HOLDINGS. Form: POWDER. Route: INTRAVENOUS

    full page →AXTLE →fda approvals ↗
    419d ago
    HADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    ›Jun 24, 2025approval418d agoTRAZODONE HYDROCHLORIDE — FDA approvalTRAZODONE HYDROCHLORIDE

    Sponsor: APOTEX INC. Form: TABLET. Route: ORAL

    full page →TRAZODONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 24, 2025approval418d agoTRAZODONE HYDROCHLORIDE — FDA approvalTRAZODONE HYDROCHLORIDE

    Sponsor: APOTEX. Form: TABLET. Route: ORAL

    full page →TRAZODONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 24, 2025approval418d agoMETHADOSE (METHADONE HYDROCHLORIDE) — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 24, 2025approval418d agoRALDESY (TRAZODONE HYDROCHLORIDE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: KAMAT. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Jun 25, 2025approval417d agoMETHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Jun 26, 2025approval416d agoPUR-WASH (PURIFIED WATER) — FDA approval

    Sponsor: NIAGARA PHARMS. Form: SOLUTION. Route: OPHTHALMIC

    full page →fda approvals ↗
    ›Jun 26, 2025approval416d agoCAPRELSA (VANDETANIB) — FDA approvalvandetanib

    Sponsor: GENZYME CORP. Form: TABLET. Route: ORAL

    full page →vandetanib →fda approvals ↗
    ›Jun 27, 2025approval415d agoSTELARA (USTEKINUMAB) — FDA approvalJOHNSON & JOHNSON

    Sponsor: CENTOCOR ORTHO BIOTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jun 27, 2025approval415d agoSTELARA (USTEKINUMAB) — FDA approvalustekinumab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →ustekinumab →fda approvals ↗
    ›Jun 27, 2025approval415d agoGAMIFANT (EMAPALUMAB-LZSG) — FDA approvalSobi Inc

    Sponsor: NOVIMMUNE S.A.. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jun 27, 2025approval415d agoPYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalPYZCHIVA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →PYZCHIVA →fda approvals ↗
    ›Jun 27, 2025approval415d agoULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approvalAlexion Pharmaceuticals Inc

    Sponsor: ALEXION PHARM. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    411d ago
    TRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: RUBICON RESEARCH. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Jul 3, 2025approval409d agoISTURISA (OSILODROSTAT PHOSPHATE) — FDA approvalosilodrostat phosphate

    Sponsor: RECORDATI RARE. Form: TABLET. Route: ORAL

    full page →osilodrostat phosphate →fda approvals ↗
    $BMY63.83-1.27%
    $PFE26.79-0.04%
    $PHAT9.5800+4.36%
    $MRK135.84+0.21%
    $ABBV249.46-0.54%
    $AMGN415.21-0.63%
    $ABBV249.46-0.54%
    $PHAT9.5800+4.36%
    $REGN803.48-0.31%
    $JNJ260.35-0.66%